{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:22:46Z","timestamp":1789017766043,"version":"build-2803163510"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"publisher","award":["20152219"],"award-info":[{"award-number":["20152219"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,5]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Natural killer\/T-cell lymphoma (NKTCL) is a rare and heterogeneous tumor type of non-Hodgkin\u2019s lymphoma (NHL) with a poor clinical outcome. There is no standardized salvage treatment failing l-asparaginase-based regimens. Here we report our retrospective results of the combined use of selinexor and PD-1 blockade (tislelizumab) in 5 patients with NKTCL who had exhausted almost all available treatments.<\/jats:p>\n <\/jats:sec>\n \n Patients and methods<\/jats:title>\n A total of 5 patients with relapsed\/refractory(R\/R) NK\/T-cell lymphomas failing prior l-asparaginase and anti-PD-1 antibody were retrospectively collected. They were treated with at least one cycle of XPO1 inhibitor plus the same anti-PD-1 antibody. Anti-PD-1 antibody (Tislelizumab) was administrated at 200 mg on day 1 every 3 weeks and selinexor doses and schedules ranged from 40 mg weekly for 2 weeks per 21-day cycle to 60 mg weekly per cycle.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Five patients with relapsed NKTCL with extensive organ involvement including 4 central nervous system (CNS) infiltration patients were included. Four patients achieved objective responses including 3 complete responses (CR) and 1 partial response (PR). After a median follow-up time of 14.5 (range, 5-22) months, 1 patient was still in remission with CR, and the other 4 patients discontinued due to disease progression with a median progression-free survival (PFS) of 6 months and median overall survival (OS) of 12 months. Four patients with CNS involvement achieved a median OS of 8 months. Our data suggest that selinexor in combination with an anti-PD-1 antibody is a promising small molecule and immunotherapy combination regimen for patients with relapsed or refractory NKTCL.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad241","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T16:48:11Z","timestamp":1691599691000},"page":"e90-e96","source":"Crossref","is-referenced-by-count":10,"title":["Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer\/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5766-1625","authenticated-orcid":false,"given":"Rong","family":"Tao","sequence":"first","affiliation":[{"name":"Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , People\u2019s Republic of China"},{"name":"Department of Lymphoma, Fudan University Shanghai Cancer Center , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanxu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , People\u2019s Republic of China"},{"name":"Department of Lymphoma, Fudan University Shanghai Cancer Center , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , People\u2019s Republic of China"},{"name":"Department of Lymphoma, Fudan University Shanghai Cancer Center , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siguo","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"2024010523411876400_CIT0001","first-page":"2460","article-title":"NK-\/T-cell lymphomas","volume-title":"Leukemia","author":"Wang","year":"2021"},{"key":"2024010523411876400_CIT0002","first-page":"2199","article-title":"Beyond first-line non-anthracycline-based chemotherapy for extranodal NK\/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease","volume-title":"Ann Oncol","author":"Lim","year":"2017 1"},{"key":"2024010523411876400_CIT0003","first-page":"25","article-title":"Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK\/T-cell lymphoma, nasal type","volume-title":"Ann Hematol","author":"Jo","year":"2017"},{"key":"2024010523411876400_CIT0004","first-page":"3175","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume-title":"Blood","author":"Kuruvilla","year":"2017 15"},{"key":"2024010523411876400_CIT0005","first-page":"417","article-title":"The exportin-1 inhibitor selinexor exerts superior antitumor activity when combined with T-cell checkpoint inhibitors","volume-title":"Mol Cancer Ther","author":"Farren","year":"2017"},{"key":"2024010523411876400_CIT0006","first-page":"152","article-title":"Comprehensive analysis of nuclear export of herpes simplex virus type 1 tegument proteins and their Epstein-Barr virus orthologs","volume-title":"Traffic","author":"Funk","year":"2019"},{"key":"2024010523411876400_CIT0007","first-page":"e0200043","article-title":"In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals","volume-title":"PLoS One","author":"Widman","year":"2018"},{"key":"2024010523411876400_CIT0008","first-page":"3059","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume-title":"J Clin Oncol","author":"Cheson","year":"2014"},{"key":"2024010523411876400_CIT0009","first-page":"5034","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume-title":"J Clin Oncol","author":"Abrey","year":"2005"},{"key":"2024010523411876400_CIT0010","first-page":"1677","article-title":"Clinical presentation, treatment, and outcomes of patients with central nervous system involvement in extranodal natural killer\/T-cell lymphoma","volume-title":"Leuk Lymphoma","author":"Nevel","year":"2019"},{"key":"2024010523411876400_CIT0011","first-page":"25","article-title":"Daratumumab monotherapy for patients with relapsed or refractory natural killer\/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase II study","volume-title":"J Hematol Oncol","author":"Huang","year":"2021"},{"key":"2024010523411876400_CIT0012","first-page":"1766","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume-title":"Ann Oncol","author":"Shi","year":"2015"},{"key":"2024010523411876400_CIT0013","first-page":"2399","article-title":"Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108","volume-title":"J Clin Oncol","author":"Barr","year":"2015"},{"key":"2024010523411876400_CIT0014","first-page":"254","article-title":"Complete remission in CD30-positive refractory extranodal NK\/T-cell lymphoma with brentuximab vedotin","volume-title":"Blood Res","author":"Kim","year":"2015"},{"key":"2024010523411876400_CIT0015","first-page":"365","article-title":"Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase II trial (ORIENT-4)","volume-title":"Signal Transduct Target Ther","author":"Tao","year":"2021"},{"key":"2024010523411876400_CIT0016","first-page":"2754","article-title":"Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: an open-label phase II study","volume-title":"Blood","author":"Kim","year":"2020"},{"key":"2024010523411876400_CIT0017","first-page":"9","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume-title":"Br J Cancer","author":"Jenkins","year":"2018"},{"key":"2024010523411876400_CIT0018","article-title":"XPO1 inhibitor (ATG-010) plus Gemox regimen for relapsed or refractory T and NK-cell lymphoma: a phase IB study","author":"Gao","year":"2021"},{"key":"2024010523411876400_CIT0019","first-page":"S756","article-title":"Phase IB study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies - the melanoma experience","volume-title":"Ann Oncol","author":"Glitza","year":"2020"},{"key":"2024010523411876400_CIT0020","first-page":"4142","article-title":"First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume-title":"J Clin Oncol","author":"Abdul Razak","year":"2016"},{"key":"2024010523411876400_CIT0021","first-page":"110503","article-title":"XPO1 target occupancy measurements confirm the selinexor recommended phase II dose","volume-title":"Oncotarget","author":"Crochiere","year":"2017"},{"key":"2024010523411876400_CIT0022","first-page":"3170","article-title":"Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer\/T-cell lymphoma","volume-title":"Haematologica","author":"Tang","year":"2021"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/1\/e90\/55119360\/oyad241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/1\/e90\/55119360\/oyad241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T18:46:28Z","timestamp":1704480388000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/1\/e90\/7250187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8,24]]},"published-print":{"date-parts":[[2024,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad241","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,8,24]]}}}